Correlation of visfatin expression with clinicopathologic characteristics of breast cancer patients
Variables | Item | Visfatin | Pa | |||
---|---|---|---|---|---|---|
Low | High | |||||
n | % | n | % | |||
Stage | I/II | 47 | 56.6 | 36 | 43.4 | 0.091 |
III/IV | 8 | 36.4 | 14 | 63.6 | ||
Grade | I/II | 41 | 55.4 | 33 | 44.6 | 0.338 |
III | 14 | 45.2 | 17 | 54.8 | ||
Age, y | ≤50 | 32 | 57.1 | 24 | 42.9 | 0.296 |
50 | 23 | 46.9 | 26 | 53.1 | ||
BMI, kg/m2 | <24 | 31 | 49.2 | 32 | 50.8 | 0.425 |
≥24 | 24 | 57.1 | 18 | 42.9 | ||
Tumor size, cm | <2 | 31 | 64.6 | 17 | 35.4 | 0.022 |
≥2 | 24 | 42.1 | 33 | 57.9 | ||
LN metastasis | 0–1 | 46 | 57.5 | 34 | 42.5 | 0.060 |
≥2 | 9 | 36.0 | 16 | 64.0 | ||
ER | Negative | 12 | 33.3 | 24 | 66.7 | 0.005 |
Positive | 43 | 62.3 | 26 | 37.7 | ||
PR | Negative | 17 | 37.8 | 28 | 62.2 | 0.009 |
Positive | 38 | 63.3 | 22 | 36.7 | ||
Her2/neu | Negative | 31 | 46.3 | 36 | 53.7 | 0.096 |
Positive | 24 | 63.2 | 14 | 36.8 |
aP value was calculated by the χ2 test.